Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





PROPOXUR								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 114-26-1; **Chemical Formula:** C11H15NO2
OSHA had no former limit for propoxur. The ACGIH has established an 8-hour TLV-TWA of 0.5 mg/m3 for this white, odorless, crystalline compound. The proposed PEL was 0.5 mg/m3 as an 8-hour TWA; NIOSH (Ex. 8-47, Table N1) concurs with this limit, and the final rule establishes it.
The oral LD(50)s in male and female rats are 83 and 86 mg/kg, respectively; for both sexes, the dermal LD(50) is greater than 2400 mg/kg (Gaines 1969/Ex. 1-320). Dietary studies in rats at levels of 7.5 mg/kg/day for 28 days or at 800 ppm for three months produced no adverse effects (Association of American Pesticide Control Officials, Inc. 1966/Ex. 1-1011). Rats were exposed to propoxur concentrations of 5, 7, 18.7, or 31.7 mg/m3 six hours/day, five days/week for 12 weeks; animals in the high-dose group showed depressed red blood cell and brain cholinesterase levels, and plasma cholinesterase was depressed by as much as 20 to 30 percent (Association of American Pesticide Control Officials, Inc. 1966/Ex. 1-1011).
In humans, a few cases of mild propoxur poisoning have been reported among sprayers of this insecticide and among residents of propoxur-treated homes (Vandekar, Hedayat, Plestina, and Ahmady 1968/Ex. 1-679). In a study of human volunteers, a single oral dose of 1.5 mg/kg propoxur caused a depression in red blood cell cholinesterase and gastrointestinal symptoms that disappeared two hours after ingestion. Oral doses of 0.75 to 1.0 mg/kg produced no symptoms but did depress erythrocyte cholinesterase (Vandekar, Plestina, and Wilhelm 1971/Ex. 1-680). The only comment on this substance was submitted by NIOSH.
In the final rule, OSHA is establishing an 8-hour TWA of 0.5 mg/m3 for propoxur. The Agency concludes that this limit will protect workers against the significant risk of cholinesterase inhibition associated with exposure to this substance at the levels formerly permitted by the absence of any OSHA limit. OSHA finds that cholinesterase inhibition is a material health impairment.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue